Repligen Corporation (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Repligen Corporation (NASDAQ:RGEN) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $179.6154.

Several research analysts have recently commented on RGEN shares. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. Evercore ISI raised their price target on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. UBS Group boosted their price objective on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. HSBC began coverage on shares of Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 target price on the stock. Finally, Canaccord Genuity Group upped their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 20,000 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $154.61, for a total value of $3,092,200.00. Following the completion of the sale, the director owned 80,743 shares in the company, valued at approximately $12,483,675.23. This trade represents a 19.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO James Bylund sold 2,191 shares of Repligen stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 49,657 shares of company stock worth $7,721,077. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new position in Repligen during the 1st quarter valued at $262,000. Jones Financial Companies Lllp boosted its stake in shares of Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after purchasing an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares during the period. Park Avenue Securities LLC bought a new position in Repligen in the second quarter worth about $340,000. Finally, Congress Asset Management Co. lifted its holdings in Repligen by 18.0% in the second quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock worth $18,962,000 after buying an additional 23,231 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 4.1%

Shares of NASDAQ RGEN opened at $169.97 on Thursday. The stock has a market capitalization of $9.57 billion, a P/E ratio of 8,502.75, a PEG ratio of 2.96 and a beta of 1.12. Repligen has a one year low of $102.96 and a one year high of $182.52. The firm’s 50 day simple moving average is $163.45 and its two-hundred day simple moving average is $142.41. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The firm’s revenue was up 21.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, analysts expect that Repligen will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.